Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the ...
Boehringer Ingelheim Limited: Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...
GlobalData on MSN3d
AlloVir and Kalaris enter merger to advance retinal disease therapies
"AlloVir and Kalaris enter merger to advance retinal disease therapies" was originally created and published by ...
moneycontrol.com10h
World Diabetes Day: Protect your eyes from diabetes with these 9 lifestyle changes
Diabetic eye disease includes conditions like diabetic retinopathy ... which can lead to more rapid progression of retinal ...
Pharmabiz1d
Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes
Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes: Ingelheim, Germany Wednesday, November 13, 2024, 10:00 Hrs [IST] Boehringer Ingelheim and the ...
Medscape1d
Researchers Identify Why Some Don’t Respond to Anti-VEGF Drugs for AMD
as well as diabetic retinal disease and other retinal illnesses. Now, Sodhi and his fellow researchers have identified the ...
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...
health.economictimes.indiatimes13h
“Spotlight on Diabetic Eye Disease: Early Detection can save sight”
Preventing diabetic eye disease involves effectively managing diabetes through ... and for type 2 diabetics, a retinal ...
EurekAlert!1d
KRISS partners with domestic university hospitals to develop disease diagnosis and treatment technology, alleviating patient burden
The Korea Research Institute of Standards and Science (KRISS) announced that they have developed an advanced disease ...
Stockhouse6d
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
This study will be a Phase 2 clinical trial to explore multiple doses of KIO-104 in patients with inflammatory retinal diseases, including posterior non-infectious uveitis and diabetic macular ... and ...
Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update
In October, Ocuphire Pharma acquired Opus Genetics, creating a leading, clinical-stage company focused on the development of gene therapy ...
FierceBiotech6d
Struggling AlloVir finds new identity by merging into eye disease biotech
AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...